Effects of GLP-1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta-Analysis
In brief
Incretin therapies lower uric acid 0.44 mg/dL and gout flares 38%
A meta-analysis of 18 randomized trials involving 77,942 people found incretin-based therapies modestly lowered uric acid and reduced gout flare incidence by 38%; hyperuricemia incidence was 39% lower. Weight loss explained most of the uric acid reduction, but the clinical importance of these effects and any weight-independent benefit remain uncertain.
- Journal
- Diabetes, obesity & metabolism (Q1)
- Published
- 8 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Young Ho Lee, Gwan Gyu Song
- PMID
- 43000185
- DOI
- 10.1111/dom.71525
Why clinicians should know about it
- Picked for Internal Medicine (top studies of the week, 15 November 2026): Meta-analysis informs gout and urate effects of diabetes therapies
Abstract
OBJECTIVES: Hyperuricemia and gout are common but underappreciated comorbidities in Type 2 diabetes (T2D), obesity and chronic kidney disease (CKD). We aimed to quantify the pooled effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists on serum uric acid (SUA), incident gout and hyperuricemia, and to determine whether these effects vary by drug class and are mediated by weight loss. METHODS: We searched PubMed/MEDLINE, Embase, CENTRAL and ClinicalTrials.gov through July 2026 for RCTs of ≥ 12 weeks' duration reporting SUA change, gout flares or hyperuricemia incidence. Random-effects meta-analysis, subgroup and sensitivity analyses and meta-regression were performed. Registered with PROSPERO (CRD420261468511). RESULTS: Eighteen RCTs (77 942 participants) met inclusion criteria. Incretin-based therapy significantly reduced SUA versus control (weighted mean difference [WMD] -0.44 mg/dL, 95% CI -0.52 to -0.35), reduced incident gout flares (hazard ratio [HR] 0.62, 95% CI 0.53-0.72), and reduced hyperuricemia incidence (odds ratio [OR] 0.61, 95% CI 0.53-0.70). Dual GIP/GLP-1 RA (tirzepatide) produced greater SUA lowering than mono GLP-1 RAs (-0.62 vs. -0.35 mg/dL, p = 0.001). Body-weight loss was a significant moderator of SUA reduction (β = -0.041 mg/dL per kg, p < 0.001), explaining 84.7% of between-trial heterogeneity, with a significant weight-independent intercept (-0.19 mg/dL, p < 0.001). The SUA reduction was robust in all sensitivity analyses, including restriction to placebo-controlled trials. GRADE certainty was high for SUA and moderate for gout flares (owing to small-study effects) and hyperuricemia incidence. CONCLUSION: Incretin-based therapies were associated with modest reductions in SUA and with a lower incidence of gout flares and hyperuricemia, an effect largely related to weight loss. The clinical relevance of these effects, and the mechanism of any weight-independent component, remains uncertain and warrant confirmation in dedicated trials.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.